Table 2 Clinical, cytogenetic and molecular features of a patient with Ph-positive CML who developed Ph-negative acute lymphoblastic leukemia after IFN-α and imatinib mesylate therapy
Date | Disease stage (Treatment) | Karyotype | BCR/ABL | |
|---|---|---|---|---|
FISH | RT-PCR | |||
8/10/2000 | CP | 46, XX, t(9;22), t(11;18), der(16), t(16;?)[25] | +ve(95%) | +ve |
3/3/2001 | CP(IFN-α) | ND | +ve(95%) | ND |
21/12/2001 | CP(IFN-α) | 45, XX,-22,16q+ t(11;18)[1]/45, XX,-22,16q+ t(9;22)t(11;18)[1]/46, XX,-22,16q+ t(9;22)t(11;18)[18]/46, XX [5] | +ve(90%) | ND |
28/11/2002 | CP(IFN-α) | ND | +ve(100%) | ND |
28/11/2003 | CP(IFN-α) | ND | +ve(90%) | ND |
6/5/2004 | CP(IFN-α) | ND | +ve(90%) | ND |
1/6/2005 | CP(IFN-α) | ND | +ve(75%) | ND |
27/1/2006 | CCR(IFN-α) | ND | -ve | ND |
8/3/2006 | CCR (IM) | ND | -ve | ND |
11/5/2006 | CCR (IM) | ND | -ve | ND |
9/8/2006 | CCR (IM) | ND | -ve | ND |
8/10/2006 | Ph-negative ALL | 46, XX [25] | -ve | -ve |
18/12/2006 | Post CT for ALL | 46, XX [25] | -ve | -ve |